Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. CureVac NV's Average Total Inventories for the quarter that ended in Mar. 2024 was $27.77 Mil. CureVac NV's Revenue for the
three
months ended in Mar. 2024 was $13.45 Mil.
CureVac NV's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 2.07.
CureVac NV's Inventory-to-Revenue for the quarter that ended in Mar. 2024
increased
from Dec. 2023 (1.06) to Dec. 2023 (2.07)
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
CureVac NV's Days Inventory for the
three
months ended in Mar. 2024 was 55.91.
Inventory Turnover measures how fast the company turns over its inventory within a year.
CureVac NV's Inventory Turnover for the quarter that ended in Mar. 2024 was 1.63.
CureVac NV Inventory-to-Revenue Historical Data
The historical data trend for CureVac NV's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CureVac NV's Inventory-to-Revenue
For the Biotechnology subindustry, CureVac NV's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CureVac NV's Inventory-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CureVac NV's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where CureVac NV's Inventory-to-Revenue falls into.
CureVac NV Inventory-to-Revenue Calculation
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
CureVac NV's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
CureVac NV's Days Inventory for the
three
months ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CureVac NV Inventory-to-Revenue Related Terms
Thank you for viewing the detailed overview of CureVac NV's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CVAC has been successfully added to your 